uniQure (NASDAQ:QURE) Trading Down 7.1% – Here’s What Happened

uniQure N.V. (NASDAQ:QURE)’s stock price fell 7.1% during mid-day trading on Wednesday . The stock traded as low as $15.84 and last traded at $15.9250. 749,247 shares were traded during trading, a decline of 76% from the average session volume of 3,170,033 shares. The stock had previously closed at $17.14.

Analysts Set New Price Targets

Several research analysts recently weighed in on QURE shares. Weiss Ratings reissued a “sell (d-)” rating on shares of uniQure in a research note on Wednesday, January 21st. Sanford C. Bernstein downgraded shares of uniQure to a “market perform” rating in a research note on Tuesday, March 3rd. Wolfe Research started coverage on shares of uniQure in a research note on Monday, February 23rd. They issued a “peer perform” rating for the company. Chardan Capital boosted their target price on shares of uniQure from $16.00 to $31.00 and gave the company a “buy” rating in a research note on Monday, March 9th. Finally, HC Wainwright reissued a “buy” rating and issued a $70.00 target price on shares of uniQure in a research note on Tuesday, March 10th. Ten investment analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $42.75.

uniQure Stock Down 6.7%

The firm’s 50 day moving average is $18.96 and its two-hundred day moving average is $29.65. The stock has a market cap of $999.46 million, a price-to-earnings ratio of -4.61 and a beta of 0.75. The company has a current ratio of 10.43, a quick ratio of 10.43 and a debt-to-equity ratio of 0.25.

uniQure (NASDAQ:QURE) last announced its earnings results on Tuesday, March 3rd. The biotechnology company reported ($0.56) earnings per share for the quarter, beating the consensus estimate of ($0.93) by $0.37. uniQure had a negative net margin of 1,236.00% and a negative return on equity of 174.03%. The firm had revenue of $5.57 million during the quarter, compared to the consensus estimate of $4.84 million. On average, sell-side analysts predict that uniQure N.V. will post -3.75 EPS for the current year.

Insider Activity at uniQure

In other news, Director Jack Kaye sold 6,390 shares of the company’s stock in a transaction dated Friday, January 9th. The shares were sold at an average price of $27.28, for a total transaction of $174,319.20. Following the completion of the transaction, the director owned 20,439 shares of the company’s stock, valued at $557,575.92. This represents a 23.82% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Robert Gut sold 25,613 shares of the company’s stock in a transaction dated Monday, January 12th. The shares were sold at an average price of $24.62, for a total transaction of $630,592.06. Following the transaction, the director directly owned 32,342 shares of the company’s stock, valued at approximately $796,260.04. This represents a 44.19% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 81,399 shares of company stock worth $1,527,645. Corporate insiders own 4.79% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the stock. Swiss National Bank acquired a new position in shares of uniQure during the 2nd quarter valued at about $1,080,000. Sanders Morris Harris LLC acquired a new position in shares of uniQure during the 3rd quarter valued at about $5,081,000. Vanguard Group Inc. increased its stake in shares of uniQure by 15.7% during the 3rd quarter. Vanguard Group Inc. now owns 1,125,108 shares of the biotechnology company’s stock valued at $65,673,000 after acquiring an additional 152,417 shares during the last quarter. Aberdeen Group plc increased its position in uniQure by 6.9% during the 3rd quarter. Aberdeen Group plc now owns 2,939,743 shares of the biotechnology company’s stock worth $171,593,000 after purchasing an additional 189,029 shares in the last quarter. Finally, Quinn Opportunity Partners LLC acquired a new stake in uniQure during the 3rd quarter worth approximately $6,281,000. Institutional investors and hedge funds own 78.83% of the company’s stock.

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.